Compliance.
Last updated: June 2025
Research use statement
All products sold by Reta Source UK Ltd are research chemicals supplied exclusively for in-vitro and laboratory research. They have not been evaluated by the MHRA or any regulatory authority for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any disease or condition.
UK regulatory status
Retatrutide (LY3437943) is a GLP-1/GIP/glucagon receptor triple agonist currently in Phase III clinical trials. It is not a controlled substance under the UK Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016 as of the date of this notice. It is not a licensed medicine. Supply is lawful for research purposes.
Buyer responsibility
The buyer is solely responsible for ensuring that the purchase, possession, and use of any product complies with the laws of their jurisdiction. Reta Source UK Ltd accepts no liability for misuse or unlawful use of products supplied.
Quality assurance
Products are tested to ≥98% purity by independent third-party laboratory analysis. A Certificate of Analysis (CoA) is available upon request for every batch. Storage and dispatch follow cold-chain protocols to maintain product integrity.
Contact
Compliance enquiries: hello@retasourceuk.com